WO2026053158 - DAZOSTINAG OR CONJUGATES THEREOF FOR TREATMENT OF NEUROENDOCRINE NEOPLASMS
National phase entry is expected:
Publication Number
WO/2026/053158
Publication Date
12.03.2026
International Application No.
PCT/IB2025/058946
International Filing Date
05.09.2025
Title **
[English]
DAZOSTINAG OR CONJUGATES THEREOF FOR TREATMENT OF NEUROENDOCRINE NEOPLASMS
[French]
DAZOSTINAG OU CONJUGUÉS ASSOCIÉS POUR LE TRAITEMENT DE NÉOPLASMES NEUROENDOCRINIENS
Applicants **
TAKEDA PHARMACEUTICAL COMPANY LIMITED
APPLEMAN, Vicky
HUANG, Harry
LINEBERRY, Neil
RAIZER, Jeffrey
ROSENTRATER, Emily
Inventors
APPLEMAN, Vicky
HUANG, Harry
LINEBERRY, Neil
RAIZER, Jeffrey
ROSENTRATER, Emily
Priority Data
63/691,940
06.09.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3507 | |
| EPO | Filing, Examination, Granting | 34822 | |
| Japan | Filing, Examination, Granting | 3421 | |
| South Korea | Filing, Examination, Granting | 4649 | |
| USA | Filing, Examination, Granting | 12540 |
Total:
58,939
Contact Us
Abstract[English]
The present disclosure provides a method of treating a neuroendocrine neoplasm in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of dazostinag or ADC-B17, or a pharmaceutically acceptable salt thereof, and optionally, an immune checkpoint inhibitor.[French]
La présente divulgation concerne une méthode de traitement d'un néoplasme neuroendocrinien chez un sujet en ayant besoin, la méthode comprenant l'administration au sujet d'une quantité thérapeutiquement efficace de dazostinag ou d'ADC-B17, ou d'un sel pharmaceutiquement acceptable de celui-ci, et éventuellement, d'un inhibiteur de point de contrôle immunitaire.